Natera has announced findings from a study evaluating its Signatera in individuals with soft tissue and bone sarcomas.

The Final Rule was mooted for implementation over a staged transition period, determined by a service’s risk level, by 2028.

Firefly Neuroscience has completed the acquisition of Evoke Neuroscience, a developer of technologies aimed at assessing ...

InBrain Neuroelectronics has won a €4m ($4.5m) grant from the Spanish Ministry of Industry and Tourism to develop its BCI ...

URA has entered the consumer diabetes space, offering a new glucose feature for its ring that uses insights from Dexcom’s CGM ...

Zimmer Biomet has adjusted its 2025 earnings forecast to $7.90-$8.10 per share, down from previous estimates falling between ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance to GE HealthCare's Aurora nuclear medicine system and ...

Tariffs, though designed as economic tools, have ripple effects that extend deeply into the regulatory framework of the ...

Endogenex has shared results from its REGENT-1 clinical study during the Digestive Disease Week (DDW) 2025 event held in San ...

Core has completed the acquisition of neurotechnology solution provider NeuroMetrix, including its Quell platform.

The FDA designation is a step forward for Neuralink as owner Elon Musk faces increasing scrutiny. The US Food and Drug ...

Canada’s UHN and U of T researchers have created a skin-based test that identifies progressive supranuclear palsy (PSP) ...